Summary:
This study is evaulating an investigational humanized monoclonal antibody to determine whether it may slow the progression of PPMS (Primary Progressive MS) The investigational drug drug is designed to target a type of white blood cells, called B-cells,that is believed to play a role in the progression of the disease. Researchers are increasingly studying the role B-cells may play in the nervous system damage that occurs in people with PPMS.
Qualified Participants Must:
• Be 18-55 years of age
•
Have been diagnosed with Primary Progressive Multiple sclerosis
Qualified Participants May Receive:
Access to the investigational drug or placebo (inactive substance). Potential long-term access to the investigational drug during and extended treatment period(not all participants will be elgible for the study extension). Study related care and monitoring ( inclduing physical examinations, neurological exams, and MRI scans.